The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing the compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.

The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.

The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.

The present invention relates to a compound for an organic optoelectronic element, represented by chemical formula I, an organic optoelectronic element employing the same, and a display device. The details of chemical formula I above are defined as in the specification.

The present invention relates to a compound for an organic optoelectronic element, represented by chemical formula I, an organic optoelectronic element employing the same, and a display device. The details of chemical formula I above are defined as in the specification.

The present disclosure provides a compound represented by formula (I):

##STR00001##

and an organic electroluminescent device including the same.

The present disclosure provides a compound represented by formula (I):

##STR00001##

and an organic electroluminescent device including the same.

The present invention provides compounds of formula (IV); ##STR00001##
or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (IV), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.

The present invention provides compounds of formula (IV); ##STR00001##
or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (IV), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.

An organic electroluminescent element using a compound represented by the following general formula (I) emits dark blue light and has small changes in the chromaticity and in the driving voltage even after driving for a long period of time: ##STR00001##
wherein R.sup.1 to R.sup.6; Q.sup.1 and Q.sup.2; X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are as defined herein.